Crohn's Disease Clinical Trial
— TECCUOfficial title:
Clinical Impact of Telemedicine in Crohn's Disease and Ulcerative Colitis: Study Teccu
Verified date | January 2017 |
Source | Instituto de Investigacion Sanitaria La Fe |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pragmatic clinical trial, randomized, controlled parallel, 3 group (group technology platform, call group and control group), developed in the monograph Reference Unit of Inflammatory Bowel Disease Valencia (single-center).
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2016 |
Est. primary completion date | December 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients aged =18 years. - Inflammatory Bowel Disease at least 6 months duration, diagnosed according to the classical criteria of Lennard-Jones - Patients with Crohn's Disease or Ulcerative Colitis with moderate or severe activity (as Harvey-Bradshaw index and May, respectively) attending IBD unit during the period of inclusion. - Patients who initiate medical treatment with immunosuppressive drugs or biological agents, or are undergoing surgical treatment (surgery is considered as a treatment for EC). - Patient consents to participate in the study and sign and date personally indicating that it has been informed of all pertinent aspects of the study. - Patient not incur the exclusion criteria Exclusion Criteria: - Patients with cognitive or sensory impairments or with insufficient command of the two official languages of Valencia, in the opinion of the health professional conduct recruitment, hinder the understanding of the issues raised in the surveys, scales or instruments used in the study always who do not have a legal representative - Patients who are unable to handle a mobile phone to participate in the study. - Patients who do not have a phone line because, if they are assigned to G_TECCU or G_AT groups could not be implemented appropriate interventions. - They are participating at the time of recruitment in any other clinical trial or experimental study. Exclusion criteria will not be participating in observational studies - Terminals and / or palliative care according to the criteria of the SECPAL (Spanish Society of Palliative Care) Patients - Patients institutionalized - They are members of the research team, the staff of the research center or health centers involved in the study, or any other person directly involved in the study. - Relatives in the first degree of consanguinity or affinity of members of the research team, the staff of the research center or health centers involved in the study, or any other person directly involved in the study - Patients presenting as primary diagnosis mental illness - Patients with active cancer diagnosis - Patients in the assessment of professional performing recruitment not considered likely to be included for specific monitoring found in another unit such as hemodialysis, transplant unit, day hospital ... - Patients who do not agree to participate in the study or not to sign the corresponding informed consent |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Instituto de Investigacion Sanitaria La Fe |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Remission | Clinical remission of patients at 6 months of follow-up using Harvey-Bradshaw index for Crohn's disease. | 6 months | |
Primary | Clinical Remission | Clinical remission of patients at 6 months of follow-up using May index for ulcerative colitis. | 6 months | |
Secondary | Health-Related Quality of Life | Health-Related Quality of Life measured by the generic Euroqol (EQ-5D) questionaire | 6 months | |
Secondary | Health-Related Quality of Life | Health-Related Quality of Life measured by the specific IBD in its reduced version (SIBDQ: Short Inflammatory Bowel Disease Questionnaire). | 6 months | |
Secondary | Patient Satisfaction | Measured by a satisfaction questionaire designed for the study. | 6 months | |
Secondary | Therapeutic adherence | Measured by the validated Morisky-Green questionaire. | 6 months | |
Secondary | Urgent and scheduled visits and urgent hospital admissions | Urgent and scheduled visits and urgent hospital admissions in the follow-up period will be captured directly systems hospital information (HIS). | 6 months | |
Secondary | Number of surgical interventions related with the pathology | 6 months | ||
Secondary | Work activity and productivity (Cronh patients) | Worrk activity and productivity measured by a validate questionaire: Vergara M. et al. Value Health 2011;14(6):859-61). | 6 months | |
Secondary | Mortality | 6 months | ||
Secondary | Directs health costs | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |